Literature DB >> 7739005

2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.

G Cristalli1, E Camaioni, S Vittori, R Volpini, P A Borea, A Conti, S Dionisotti, E Ongini, A Monopoli.   

Abstract

A series of new 2-aralkynyl and 2-heteroaralkynyl derivatives of NECA were synthesized and studied in binding and functional assays to assess their potency for the A2a compared to A1 adenosine receptors. Compounds bearing an aromatic or heteroaromatic ring, conjugated to the triple bond, showed generally weaker activity at the A2a receptor and lower selectivity (A2a vs A1) than the alkylakynyl derivatives previously reported. However, the (4-formylphenyl)-ethynyl derivative 17 showed affinity in the low nanomolar range and high selectivity (about 160-fold) for the A2a receptor. The presence of heteroatoms improved vasorelaxant activity, the 2-thiazolylethynyl derivative 30 being the most potent in the series. Introduction of methylene groups between the triple bond and the phenyl ring favored the A2a binding affinity, and the 5-phenyl-1-pentynyl derivative 24 was found to be highly potent and selective (about 180-fold) at A2a receptors. With regard to antiplatelet activity, the presence of aromatic or heteroaromatic rings decreased potency in comparison with that of NECA and of N-ethyl-1'-deoxy-1'-(6-amino-2-hexynyl-9H-purin-9-yl)-beta-D-ribofura nuronamide (HENECA). Introduction of a methylene group was effective in increasing antiaggregatory potency only when this group is linked to a heteroatom (31-35). From these data and those previously reported, the structure-activity relationships derived for the 2-alkynyl-substituted ribose uronamides would indicate that potentiation of A2a receptor affinity could be obtained by aromatic rings not conjugated with the triple bond or by heteroaromatic groups. As for A2a receptors on platelets, the presence of aromatic rings, either conjugated or unconjugated to the triple bond, is detrimental for the antiaggregatory activity. However, the introduction of polar groups alpha to the triple bond strongly increases the potency when steric hindrance is avoided. Some of the compounds included in this series retain interesting vasodilating properties and merit further investigation for their potential in the treatment of cardiovascular disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7739005     DOI: 10.1021/jm00009a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

Review 1.  Behavioral and neurochemical effects of proline.

Authors:  Angela T S Wyse; Carlos Alexandre Netto
Journal:  Metab Brain Dis       Date:  2011-06-04       Impact factor: 3.584

Review 2.  Adenosine and ischemic preconditioning.

Authors:  B T Liang; K A Jacobson
Journal:  Curr Pharm Des       Date:  1999-12       Impact factor: 3.116

Review 3.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

4.  2- and 8-alkynyl-9-ethyladenines: Synthesis and biological activity at human and rat adenosine receptors.

Authors:  Rosaria Volpini; Stefano Costanzi; Catia Lambertucci; Sauro Vittori; Claudia Martini; M Letizia Trincavelli; Karl-Norbert Klotz; Gloria Cristalli
Journal:  Purinergic Signal       Date:  2005-03-17       Impact factor: 3.765

Review 5.  Non-Nucleoside Agonists of the Adenosine Receptors: An Overview.

Authors:  Diego Dal Ben; Catia Lambertucci; Michela Buccioni; Aleix Martí Navia; Gabriella Marucci; Andrea Spinaci; Rosaria Volpini
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-08

6.  Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists.

Authors:  P G Baraldi; B Cacciari; M J Pineda de Las Infantas; R Romagnoli; G Spalluto; R Volpini; S Costanzi; S Vittori; G Cristalli; N Melman; K S Park; X D Ji; K A Jacobson
Journal:  J Med Chem       Date:  1998-08-13       Impact factor: 8.039

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.